

**Fișa de verificare a îndeplinirii standardelor minimale  
(valabilă pentru obținerea atestatului de abilitare în Domeniul Medicină)  
(în conformitate cu O.M. 6129/20.12.2016)**

**Candidat Conf.Dr.Anca-Simona Bojan**

Nr. Crt.	Activitatea	Tipul activităților	Standarde minimale abilitare	Note asupra metodei de calcul	Gradul de îndeplinire
0	1	2	3	4	5
1.	Cercetare	a. Articole <i>in extenso</i> în reviste cotate ISI Thomson Reuters (articole în reviste cu factor de impact) în calitate de autor principal	10 articole	<p>În analiză vor fi incluse articole <i>in extenso</i> originale și reviews.</p> <p>Autorul sau autorii principali ai unei publicații se consideră a fi oricare dintre următorii:</p> <ul style="list-style-type: none"> <li>a. Primul autor</li> <li>b. Autorul corespondent</li> <li>c. Alți autori, a căror contribuție este indicată explicit în cadrul publicației a fi egală cu contribuția primului autor sau a autorului corespondent</li> <li>d. Ultimul autor</li> </ul>	<p style="text-align: center;">Îndeplinit</p> <p>1. Trifa AP, Bănescu C, Tevet M, Bojan A, Dima D, Urian L, Török Vistai T, Popov VM, Zdrenghea M, Petrov L, Vasilache A, Murat M, Georgescu D, Popescu M, Pătrinoiu O, Balea M, Costache R, Coleș E, Șaguna C, Berbec N, Vlădăreanu AM, Mihăilă RG, Bumbea H, Cucuianu A, Popp RA. TERT rs2736100 A&gt;C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms – a multicentric study on 529 patients. <i>British Journal of Haematology</i>, 2016, 174(2), 218-226.</p> <p><a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.14041">https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.14041</a>.</p> <p>–autor cu drepturi egale; IF-5,812, Q1</p> <p><u>TERT rs2736100 A &gt; C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients-Web of Science Core Collection</u></p> <p>2. Berce C, Lucan C, Petrushev B, Boca S, Miclean M, Sarpataki O, Astilean S, Buzoianu A, Tomuleasa C, Bojan A. In vivo assessment of bone marrow toxicity by gold nanoparticle-based bioconjugates in CrI:CD1(ICR) mice. <i>Int J Nanomedicine</i> 2016;11: 5261-5273</p> <p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012637/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012637/</a>.</p> <p>-ultim autor, IF-4,383,Q1</p> <p><u>In vivo assessment of bone marrow toxicity by gold nanoparticle-based bioconjugates in CrI:CD1(ICR) mice-Web of Science Core Collection</u></p> <p>3. Frinc I, Dima D, Chitic M, Berce C, Berindan-Neagoe J, Tat T, Tanase A, Tomuleasa C, Bojan A. Transthoracic ultrasonography for the follow-up of a chronic lymphocytic leukemia patient with chemotherapy-induced immunosuppression prior to allogeneic stem cell transplantation. <i>Med Ultrason</i> 2017, Vol. 19, no. 3, 330-332</p>

<http://medultrason.ro/medultrason/index.php/medultrason/article/view/976>

-ultim autor, IF-1,611

Transthoracic ultrasonography for the follow-up of a chronic lymphocytic leukemia patient with chemotherapy-induced immunosuppression prior to allogeneic stem cell transplantation. A case report-Web of Science Core Collection

4. Trifa AP, Bănescu C, Bojan AS, Voina CM, Popa S, Vișan S, Ciubean AD, Tripon F, Dima D, Popov VM, Vesa SC, Andreescu M, Torok-Vistai T, Mihăilă RG, Berbec N, Macarie I, Coliță A, Iordache M, Cătană AC, Fărcaș MF, Tomuleasa C, Vasile K, Truică C, Todincă A, Pop-Muntean L, Manolache R, Bumbea H, Vlădăreanu AM, Găman M, Ciufu C, Popp RA. MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. American Journal of Hematology. 2018; 93(1):100-106

<https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.24946>

-autor cu drepturi egale, IF-5,303,Q1

MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients-Web of Science Core Collection

5. Lighezan DL, Anca S, Bojan A, Iancu M, Pop RM, Gligor-Popa S, Tripon F, Cosma S, Tomuleasa C, Dima D, Zdrenghea M, Fetica B, Ionita I, Gaál IO, Vișan S, Mirea AM, Popp RA, Florea M, Arănciu C, Petrescu L, Pop IV, Bănescu C, Trifa AP. TET2 rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis. Journal of personalized Medicine 2020;10 (4):259

<https://www.mdpi.com/2075-4426/10/4/259>.

-autor cu drepturi egale, IF-4,945 Q1

TET2 rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis-Web of Science Core Collection

6. Bojan A, Torok-Vistai T, Parvu A. Assessment and Management of Cardiotoxicity in Hematologic Malignancies. Disease Markers 2021;1-10, article number: 6616265

prim autor, IF-3,434

<https://www.hindawi.com/journals/dm/2021/6616265/>

Assessment and Management of Cardiotoxicity in Hematologic Malignancies-Web of Science Core Collection

7. Parvu A, Orasan OH, Pop SV, Zsoldos AI, Catana C, Deac IS, Bojan AS. Efficacy and safety of thrombopoietin receptor agonists in modern treatment of immune thrombocytopenia. Farmacia. 2021,69(2):219-230

[https://farmaciajournal.com/wp-content/uploads/art-05-Parvu\\_Bojan\\_219-230.pdf](https://farmaciajournal.com/wp-content/uploads/art-05-Parvu_Bojan_219-230.pdf)

EFFICACY AND SAFETY OF THROMBOPOIETIN RECEPTOR AGONISTS IN MODERN TREATMENT OF IMMUNE

THROMBOCYTOPENIA-Web of Science Core Collection

ultim autor, IF-1,433

8. Bojan A, Parvu A, Zsoldos IA, Torok T, Farcas AD. Macrophage activation syndrome: A diagnostic challenge. *Experimental and therapeutic medicine*. 2021, 22(904):1-9

prim autor, IF-2,447

<https://www.spandidos-publications.com/10.3892/etm.2021.10336>

Macrophage activation syndrome: A diagnostic challenge (Review)-Web of Science Core Collection

9. Burz C, Bojan A, Balacescu L, Pop VV, Silaghi C, Lupan I, Aldea C, Sur D, Samasca G, Cainap C, Chiorean B. Interleukin 8 as predictive factor for response to chemotherapy in colorectal cancer patients. *Acta clinica belgica* 76 (2): 113-118

<https://doi.org/10.1080/17843286.2019.1680133>

Interleukin 8 as predictive factor for response to chemotherapy in colorectal cancer patients-Web of Science Core Collection.

autor cu drepturi egale, IF-1.264

10. Pop V , Parvu A., Craciun A., Farcas AD, Tomoaia G., Bojan A . Modern markers for evaluating bone disease in multiple myeloma (Review)-*Experimental and Therapeutic Medicine*; 22: 1329, 2021

prim autor, IF – 2,447

<https://www.spandidos-publications.com/10.3892/etm.2021.10764>

Modern markers for evaluating bone disease in multiple myeloma-Web of Science Core Collection

11.DamianMT, Vulturar R , Login CC, Damian L , Chis A, Bojan A. Anemia in Sports: A Narrative Review; *Life* 2021, 11(9), 987

ultim autor, IF –3,817

<https://www.mdpi.com/2075-1729/11/9/987>

12. Mocan-Hognogi DL ,Tranca S, Farcas AD , Mocan-Hognogi RF, Părvu AV7, Bojan AS, Immune Checkpoint Inhibitors and the Heart (Review);*Frontiers in Cardiovascular Medicine*;2021,8,726426

ultim autor, IF-6,050

<https://www.webofscience-com.am.e-plarmination.ro/wos/woscc/summary/768345af-b4d8-4799-8dde-6c7975954349-0f8e5173/relevance/1>

**b. (ISI)  
Factor  
cumulat de  
Impact  
autor  
principal  
(FCIAP)**

minim 10  
IF=5,303+  
5,812+4,3  
83+3,69+  
0,4+0,4+2  
,738+1,35  
+1,785+1,

O revistă cotate ISI este o revistă pentru care Thomson Reuters calculează și publică factorul de impact în „Journal Citation Reports”  
Factorul cumulat de Impact va fi calculat pentru articolele la care candidatul este autor principal (FCIAP=suma

Îndeplinit

40,499


		111=27,17 2	factorilor de impact ai articolelor publicate de autor in calitate de autor principal in reviste cotate ISI)	
	<b>c. Articole in extenso in reviste cotate ISI Thomson Reuters in calitate de coautor</b>	minim 5 articole		<p>Îndeplinit</p> <p>1, Sanda Boca, Ciprian Lucan, Ioana Frânc, Bobe Petrushev, Timea Simin, Cristian Berce, Grigore Aristide Gafencu, Delia Dima, Alina Tănase, Sonia Selicean, Valentina Pileczki, Laura Pop, Vlad Moșoiu, Anca Burzoianu, Adrian Florea, Alexandru Irimie, Simion Aștilean, <b>Anca Bojan</b>, Ioana Berindean-Neagoe, Ciprian Tomuleasa. Gold nanoparticles conjugated with Rituximab for the treatment of chronic lymphocytic leukemia. <i>Farmacia</i>, 2016, 64, 5: 688-698. IF-1,348</p> <p><a href="https://www.researchgate.net/profile/310439788">https://www.researchgate.net/profile/310439788</a></p> <p>2. Adrian P. Trifa, Claudia Bănescu, Delia Dima, <b>Anca S. Bojan</b>, Mihaela Tevet, Valeriu G. Moldovan, Ștefan C. Vesa, Meilin Murat, Ioan V. Pop, Cristina Skrypnuk &amp; Radu A. Popp. Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C&gt;T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms. <i>Hematology</i> 2016, 21 (9): 520-525. IF-1,650 <a href="https://www.tandfonline.com/doi/abs/10.1080/10245332.2016.1163889">https://www.tandfonline.com/doi/abs/10.1080/10245332.2016.1163889</a>.</p> <p>3, Adrian P Trifa, Claudia Bănescu, Cristian M Voina, Ștefana Popa, Tünde Török-Vistai, <b>Anca S Bojan</b>, Delia Dima, Mihnea Zdrengeha, Bogdan Fetica, Simona Vișan, Ciprian Tomuleasa, Andrada Pârnu, Laura Urian, Bogdan Pop, Viola M Popov, Mihaela Andreescu, Radu A Popp. Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycythemia vera and essential thrombocythemia. <i>Blood Cells Mol Dis</i> 2018 Nov; 73: 45-46. <a href="https://pubmed.ncbi.nlm.nih.gov/30249383/">https://pubmed.ncbi.nlm.nih.gov/30249383/</a>. IF-2,460, Q2</p> <p>4, Raluca-Ana Rusu, Dana Sirbu, Daniela Curșeu, Bogdana Năsu, Mădălina Sava, Ștefan Cristian Vesa, <b>Anca Bojan</b>, Cosmin Lisencu and Monica Popa. Chemotherapy-related infectious complications in patients with Hematologic malignancies. <i>J. Med. Sci</i> 2018, 23:68. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091125/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091125/</a>. IF-2,284, Q2</p> <p>5, Ciprian Tomuleasa, Sonia Selicean, Grigore Gafencu, Bobe Petrushev, Laura Pop, Cristian Berce, Anca Jurj, Adrian Trifa, Ana Maria Rosu, Sergiu Pasca, Lorand Magdo, Mihnea Zdrengeha, Delia Dima MD, Alina Tanase, Ioana Frinc, <b>Anca Bojan</b>, Ioana Berindan-Neagoe, Gabriel Ghiaur, Ștefan O. Ciurea. Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis. <i>Journal of Cellular Physiology</i>, 2018, 233(1); 422-433. <a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/jcp.25902">https://onlinelibrary.wiley.com/doi/abs/10.1002/jcp.25902</a>. IF-4,522, Q1</p> <p>6. Jerome Dobrowolski, Sergiu Pasca, Patric Teodorescu, Cristina Selicean, Ioana Rus, Mihnea Zdrengeha, <b>Anca Bojan</b>, Adrian Trifa, Bogdan Fetica, Bobe Petrushev, Ana-Maria Rosu, Ioana Berindan-Neagoe, Ciprian Tomuleasa and Delia Dima. Persistent Basophilia May Suggest an "Accelerated Phase" in the Evolution of CALR-Positive Primary Myelofibrosis Toward Acute Myeloid Leukemia. <i>Front.Oncol.</i> sept 2019, 9, 872. <a href="https://www.frontiersin.org/articles/10.3389/fonc.2019.00872/full">https://www.frontiersin.org/articles/10.3389/fonc.2019.00872/full</a>. IF-4,25 Q1</p> <p>7. Cristina Turcas, Vlad Moșoiu, Andrei Ștefancu, Ancuta Jurj, Ștefania D. Iancu, Patric Teodorescu, Sergiu Pasca, <b>Anca Bojan</b>, Adrian Trifa, Sabina Iluta, Alina-Andreea Zimta, Bobe Petrushev, Mihnea Zdrengeha, Horia Bumba, Daniel Coriu, Delia Dima, Nicolae Leopold and Ciprian Tomuleasa. SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia? <i>Front Oncol.</i> June 2020, 1024-1036.</p>

			<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336895/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336895/</a>. IF-4,848 Q1</p> <p>8. Sergiu Pasca, Cristina Turcas, Ancuta Jurj, Patric Teodorescu, Sabina Iluta, Ionut Hotea, <b>Anca Bojan</b>, Cristina Selicean, Bogdan Fetica, Bobe Petrushev, Vlad Moisoiu, Alina-Andreea Zimta, Valentina Sas, Catalin Constantinescu, Mihnea Zdrengheta, Delia Dima and Ciprian Tomuleasa. The Influence of Methylating Mutations on Acute Myeloid Leukemia: Preliminary Analysis on 56 Patients. <i>Diagnostics</i> 2020 10, 5, 263.</p> <p><a href="https://doi.org/10.3390/diagnostics10050263">https://doi.org/10.3390/diagnostics10050263</a>. IF-2,36, Q2</p> <p>9. Adrian P. Trifa, Diana L. Lighezan, Cristina Jucan, Florin Tripon, Dana R. Arbore, <b>Anca Bojan</b>, Ștefana Gligor-Popa, Raluca M. Pop, Delia Dima, Claudia Băncescu. SH2B3 (LNK) rs3184504 polymorphism is correlated with JAK2 V617F-positive myeloproliferative neoplasms. <i>Rev. Rom. Med. Lab</i> 2020, 28; 3; 267-277.</p> <p><a href="https://content.sciendo.com/view/journals/rmlm/28/3/article-p267.xml">https://content.sciendo.com/view/journals/rmlm/28/3/article-p267.xml</a>. IF-0.945</p> <p>10. Sas V, Blag C, Pasca S, Popa G, Marian M, Schnell C, Voda D, Arghirescu ST, Teodorescu P, Iluta S, Turcas C, Selicean C, <b>Bojan A</b>, Zdrengheta M, Serban M, Dima D, Zaharie G, Colita A, Man S, Tomuleasa C. Baseline characteristics of a nationwide cohort of pediatric patients with acute leukemias of Down syndrome. <i>Journal of B.U.O.N</i> 2020, 25(6), 2737-2746.</p> <p><a href="https://europepmc.org/article/med/33455121">https://europepmc.org/article/med/33455121</a>. IF-1,695, Q3</p> <p>11. Ciprian Tomuleasa, Sabina Iluta, Sergiu Pasca, Andrei Roman, Doina Piciu, Ciprian Jitaru, Patric Teodorescu, Ioana Rus, <b>Anca Bojan</b>, Delia Dima, Mihnea Zdrengheta &amp; Bobe Petrushev. Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab. <i>International Journal of Hematology</i>, 2020, 112: 597-598.</p> <p><a href="https://link.springer.com/article/10.1007/s12185-020-02989-5">https://link.springer.com/article/10.1007/s12185-020-02989-5</a> IF-2,245 Q2</p>
<b>d. Index Hirsch</b>	minim 6	Va fi luat în considerare Indexul Hirsch calculat utilizând ISI Web of Science, Core Collection, Thomson Reuters	<p>Îndeplinit</p> <p>7</p>


AUTHOR: (Dojan, G)

Time span=1975-2020; Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC.

Total Publications by Year



Sum of Times Cited by Year



Results for  
Sum of the  
Average C  
h-index

42  
161  
3.03  
7

Cluj-Napoca,

22.10.2021

Semnatura